

- primary (Raynaud's disease), 47e-3, 1648-1649
 secondary causes of, 1648t, 1649
 in Sjögren's syndrome, 2167, 2167t
 in systemic sclerosis, 376, 1649, 2155, 2155t, 2159, 2160f
 treatment of, 1649, 2164, 2168f
- Rb. *See* Retinoblastoma protein (Rb)
- Rb gene mutations
 in bladder cancer, 576
 cancers associated with, 101e-6t
 in lung cancer, 507, 509
 in parathyroid carcinoma, 2472
 in retinoblastoma, 440
 in soft tissue sarcoma, 119e-1
- R-binder protein, 350e-1
- RCC. *See* Renal cell carcinoma (RCC)
- RCRI (Revised Cardiac Risk Index), 52, 53f, 53t
- RDW (red blood cell distribution width), 81e-1, 393
- Reactive arthritis (Reiter's syndrome), 2173
 after nontyphoidal *Salmonella* infections, 1054
 after *Shigella* infections, 1057
 after *Yersinia* infections, 1077
C. trachomatis, 1168, 1170t
 clinical features of, 837, 2174
 aortic aneurysm, 1638
 aortitis, 290e-3, 1638
 cutaneous, 353, 353t
 diarrhea, 266-267
 oral, 237, 2174
 diagnosis of, 2175
 epidemiology of, 2173-2174
 etiology of, 2174
 vs. gonococcal arthritis, 1006, 1007f, 2175
 historic background of, 2173
 in HIV infection, 1261
 HLA gene association with, 373e-7, 373e-8t
 vs. Lyme arthritis, 1152
 pathogenesis of, 2174
 pathology of, 2174
 vs. relapsing polychondritis, 2204
 treatment of, 1078, 2175
- Reactive hyperemia, 1648
- Reactive lymphocytes, 81e-2
- Reactive oxygen species (ROS)
 in aging, 85e-8
 damage to mitochondrial DNA by, 85e-8-9, 85e-8f
 in endothelium, 265e-2
 generation of, 386
 in hyperbaric oxygen therapy, 477e-1, 477e-2f
 skin damage caused by, 386
- Reactive skin decontamination lotion (RSDL), 262e-6
- "Readback," 12e-2
- Reading, assessment of, 177
- Rebound tenderness, 106
- Rebuck skin window test, 423
- Receiver operating characteristic (ROC) curve, 21, 22f
- Receptor tyrosine kinase, 102e-3, 102e-4f, 400e-1t
- Receptor tyrosine kinase receptors, 102e-9f
- Recessive disorders, 438-439, 438f
- Reciprocal translocation, 83e-5, 83e-5f
- RECIST (Response Evaluation Criteria in Solid Tumors), 103e-5, 472, 552
- Recluse spider bite, 2747
- Recombinant tissue plasminogen activator (rtPA). *See* Alteplase (rtPA)
- Recombination, genetic, 428, 429f
- Recommended dietary allowance, 95e-1
- Recoverin, 372e-25t, 614t
- Rectal bleeding
 in colorectal cancer. *See* Colorectal cancer
 in hemorrhoidal disease. *See* Hemorrhoidal disease
 in rectal prolapse, 1974
 in ulcerative colitis, 1952, 1952t
- Rectal cancer, 543. *See also* Colorectal cancer
- Rectal neuroendocrine tumors (carcinoids), 560t, 563, 564, 567. *See also* Gastrointestinal neuroendocrine tumors (GI-NETs)
- Rectal prolapse, 1973
 clinical features of, 1974, 1974f
 epidemiology of, 1973-1974
 pathophysiology of, 1974
 treatment of, 1974-1975, 1975f
- Rectal snip, 245e-3-4
- Rectal temperatures, 124
- Rectoanal (anorectal) angle, 265, 265f
- Rectocele, 274
- Rectopexy, 1974-1975, 1975f
- Rectus sheath, hematoma of, 105
- Red blood cell(s)
 agglutination of, 81e-1, 81e-3f
 in anemia, 392-393. *See also* Anemia
 antigens and antibodies, 138e-1-2, 138e-1t
 complement activation and, 661f
 excess of. *See* Polycythemia
 folate in, 648
 fragmented, 81e-4f
 glycolysis in, 650, 650f
 hematopoietic differentiation of, 89e-3f
 immune destruction of, 658, 659f
 iron content in, 626
 life cycle of, 626, 650
 mechanical destruction of, 657, 657t
 membrane-cytoskeleton complex of, 651, 651f
 nucleated, 81e-5f
 osmotic fragility of, 651
 in peripheral blood smear, 81e-1, 81e-2-7f
 production of, 392, 392f
 protoporphyrin levels in, 627f, 628
 redox metabolism in, 654f
 transfusions. *See* Transfusion(s)
 urinary casts, 62e-11f
- Red blood cell distribution width (RDW), 81e-1, 393
- Red blood cell indices, 393, 394t
- Red blood cell scintigraphy, 279
- Red blood cell survival study, 650
- Red cell anion exchanger (AE1), 309
- Red clover, 404t
- Red hair color (RHC) phenotype, 494
- Red hepatization, 804
- Red light, for basal cell carcinoma, 386
- Red man syndrome, 381, 938t, 942
- Red pulp, of spleen, 409, 410f
- "Red tide," 2743
- 5 α -Reductase, 332
- 5 α -Reductase inhibitors, 478, 587
- 5 α -Reductase type 2 deficiency, 2353
- Reductionism, 87e-1, 87e-3
- Reduviid bugs, 1560, 2750
- REE (resting energy expenditure), 98e-4
- Reed-Sternberg cells, 81e-11f, 709f
- Reentry, 273e-4, 273e-4f
- Refeeding edema, 253
- Refeeding syndrome, 460
- Reference values. *See* Clinical laboratory tests, reference values for
- Referred pain, 88
 in abdominal diseases, 104t, 105
 to back, 111, 118
 convergence-projection hypothesis of, 89f
- Reflex(es), testing of, 2538-2539. *See also specific reflexes*
- Reflexology, 14e-1t
- Reflex sympathetic dystrophy. *See* Complex regional pain syndrome (CRPS)
- Reflex syncope. *See* Syncope, neurally mediated
- Reflux nephropathy, 1859-1860, 1860f
- Refractive state, 195
- Refractory anemias, 669, 669t. *See also* Myelodysplasia
- Refractory cytopenia with multilineage dysplasia, 669t
- Refractory neutropenia, 669t
- Refractory thrombocytopenia, 669t
- Refsum's disease, 206, 451e-4t, 2681
- Refusal of care, 17e-2, 66
- Regenerative medicine, 453
- Registries, 25
- Regorafenib
 action and targets of, 102e-5t, 103e-18t
 adverse effects of, 103e-18t
 for colorectal cancer, 103e-19
 for gastrointestinal stromal tumor, 536
- Regulatory failure, 15e-1
- Regurgitation
 in achalasia, 1904
 definition of, 258
 in esophageal disease, 1901
 in GERD, 1907
 nasal, 256
- Rehabilitation
 in alcohol use disorder, 2728
 in ischemic stroke management, 2563
 in opiate use disorders, 468e-3-4
 pulmonary, 47e-4, 1706
 in spinal cord disorders, 2660-2661, 2660t
- Reifenstein's syndrome (partial androgen insensitivity syndrome), 2355
- Reiter's syndrome. *See* Reactive arthritis (Reiter's syndrome)
- Rejection
 HLA in, 373e-5-6
 inflammatory mediators in, 372e-29t
 in kidney transplantation, 1827, 1829
 in liver transplantation, 366e-3f, 2071-2072, 2073
 in lung transplantation, 320e-3
 treatment of, 372e-30, 372e-31
- Relapsing fever
 clinical features of, 126, 152e-5t, 167e-1-2, 1147
 diagnosis of, 152e-5t, 1147-1148, 1148f
 epidemiology of, 1146
 etiology of, 1146, 1146t
 global considerations in, 1146
 incubation period for, 152e-5t
 louse-borne, 1146
 pathogenesis of, 1146-1147
 prevention of, 1149
 prognosis of, 1148-1149
 in returning war veterans, 152e-5t
 treatment of, 152e-5t, 1148, 1148f
- Relapsing polychondritis, 2202
 aortic aneurysm in, 1638
 aortitis in, 1638
 clinical features of, 1443, 2193, 2203-2204, 2203f, 2203t
 diagnosis of, 2204
 differential diagnosis of, 2204
 disorders associated with, 2202, 2202t
 incidence of, 2202
 pathogenesis of, 2202-2203
 pathology of, 2202
 prognosis of, 2204
 treatment of, 2204
- Relative afferent pupil defect, 196, 196f
- Relative bradycardia (Faget's sign), 763, 763t
- Relative risk, 373e-7
- Relaxin, 2378
- REL gene mutations, 101e-2t, 101e-3t
- Reminder systems, 30
- REM sleep, 184-185, 185f
- REM sleep behavior disorder, 192-193, 194v, 214-215, 2618
- Renal abscess, 851
- Renal agenesis/dysgenesis, 48, 333e-1
- Renal amyloidosis, 62e-6f, 1845
- Renal artery stenosis, 1627
 azotemia in, 292
 diagnosis of, 1618, 1628, 1628t
 hyperaldosteronism and, 306
 incidence of, 1627
 pathophysiology of, 1627-1628
 treatment of, 1618, 1628-1629, 1629t
- Renal artery thrombosis, 292
- Renal biopsy
 in acute interstitial nephritis, 62e-10f
 in acute kidney injury, 62e-10f, 1808
 in acute nephritic syndromes, 62e-1-6f
 in Alport's syndrome, 62e-8f, 1847
 in antiglomerular basement membrane disease, 62e-6f, 1839